Involvement of a NO-cyclic GMP-PKG signaling pathway in nitrous oxide-induced antinociception in mice.
The antinociceptive effect of nitrous oxide (N(2)O) is dependent on nitric oxide (NO); however, the next step in the pathway activated by NO is undetermined. The present study was conducted to test the hypothesis that a N(2)O action involves sequential activation of NO synthase, soluble guanylyl cyclase and protein kinase G to induce an antinociceptive effect in mice. The antinociceptive responsiveness of male NIH Swiss mice to N(2)O was assessed using the acetic acid abdominal constriction test. Different groups of mice were pretreated with either saline, the NO scavenger 2-(4-carboxyphenyl)-4,5-dihydro-4,4,5,5-tetramethyl-1H-imidazolyl-1-oxy-3-oxide (carboxy-PTIO), the guanylyl cyclase-inhibitor 1H-[1,2,4]-oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ), the protein kinase G-inhibitor Rp-isomer of 8-(4-chlorophenylthio)-guanosine-3',5'-cyclic monophosphorothioate (Rp-8-pCPT-cGMPS) or the selective phosphodiesterase V-inhibitor 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-8-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2,7-naphthyridine-3-carboxylic acid methyl ester hydrochloride (T 0156). Vehicle (saline)-pretreated mice responded to N(2)O in a concentration-dependent manner. This antinociceptive effect was antagonized by systemic pretreatment with carboxy-PTIO and ODQ and central pretreatment with Rp-8-pCPT-cGMPS. In each case, the dose-response curve for N(2)O was progressively shifted to the right by increasing the dose of each pretreatment drug. On the other hand, N(2)O-induced antinociception was enhanced by systemic pretreatment with T 0156; the dose-response curve for N(2)O was shifted to the left. The ATP-sensitive potassium channel blocker glibenclamide was without influence on the antinociceptive effect of N(2)O. These results support the hypothesis that N(2)O-induced antinociception in mice is mediated by a NO-cyclic GMP-PKG pathway.
Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, WA 99164-6534, USA.
Yao
Y
Zhang
Lindsay P
LP
Quock
Eunhee
E
Chung
Yusuke
Y
Ohgami
Raymond M
RM
Quock
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D001565:Benzoates / Q000494:pharmacology; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D017869:Cyclic GMP-Dependent Protein Kinases / Q000378:metabolism*; D005905:Glyburide / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D051379:Mice; D009287:Naphthyridines / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism*; D009609:Nitrous Oxide / Q000494:pharmacology*; D010069:Oxadiazoles / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects*; D013873:Thionucleotides / Q000494:pharmacology
C095284:1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one; C090860:8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate; D000700:Analgesics; D001565:Benzoates; D007093:Imidazoles; D009287:Naphthyridines; D010069:Oxadiazoles; D011743:Pyrimidines; D011810:Quinoxalines; C473961:T0156; D013873:Thionucleotides; C079393:1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole; D009569:Nitric Oxide; D017869:Cyclic GMP-Dependent Protein Kinases; D006152:Cyclic GMP; D009609:Nitrous Oxide; D005905:Glyburide
Inflamm Res. 2007 Feb;56(2):83-8
17431745
Proc Soc Exp Biol Med. 1957 Aug-Sep;95(4):729-31
13465785
J Pharmacol Exp Ther. 1970 Nov;175(2):435-42
4394803
Eur J Pharmacol. 1990 Jan 3;175(1):97-100
2157601
Pharmacol Biochem Behav. 2000 Feb;65(2):217-21
10672972
Brain Res. 2005 Mar 15;1038(1):113-7
15748880
Am J Physiol Regul Integr Comp Physiol. 2002 May;282(5):R1436-42
11959687
Eur J Pharmacol. 2010 Jan 25;626(2-3):234-8
19818753
J Pharmacol Exp Ther. 2003 Aug;306(2):484-9
12721331
Br J Pharmacol. 1980 Jul;69(3):503-12
6249436
J Biomed Sci. 2000 Jul-Aug;7(4):299-303
10895052
Synapse. 2010 Jun;64(6):460-6
20175220
Eur J Pharmacol. 1992 Sep 22;220(2-3):271-2
1425999
Eur J Pharmacol. 2002 Dec 5;456(1-3):91-8
12450574
Biochemistry. 1993 Jan 26;32(3):827-32
8422387
Brain Res. 1995 Mar 27;675(1-2):190-4
7796128
Endocrine. 2005 Nov;28(2):209-16
16388095
Learn Mem. 2008 Oct 02;15(10):792-805
18832566
Eur J Pharmacol. 2002 Nov 1;454(1):19-23
12409000
Eur J Pharmacol. 1992 May 27;216(1):139-40
1382021
Brain Res. 2008 May 13;1209:1-7
18406400
Neuroscience. 2006;138(1):245-56
16368196
J Pharmacol Exp Ther. 1949 Jun;96(2):99-113
18152921
Neurosci Lett. 1994 Nov 7;181(1-2):27-30
7534892
Brain Res. 1991 May 17;549(1):162-4
1832578
Br J Pharmacol Chemother. 1957 Mar;12(1):12-5
13413144
J Pharmacol Exp Ther. 1997 Aug;282(2):977-84
9262366
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3680-5
14990791
J Neuroendocrinol. 2003 Jul;15(7):667-76
12787051
Neuropharmacology. 1993 Nov;32(11):1267-77
7509051
J Cardiovasc Electrophysiol. 1993 Feb;4(1):38-47
8287235
Eur J Pharmacol. 1994 Oct 14;269(2):265-8
7851503
Brain Res. 2003 Apr 4;968(1):167-70
12644275
Neurochem Int. 2004 Nov;45(6):875-84
15312982
Mol Pharmacol. 1995 Aug;48(2):184-8
7544433
Behav Brain Res. 2004 Jul 9;152(2):361-3
15196804
Eur J Pharmacol. 1993 May 12;236(1):137-42
8391452
Behav Neurosci. 2004 Jun;118(3):648-52
15174944
J Pharmacol Exp Ther. 1994 May;269(2):601-8
8182526
Biochim Biophys Acta. 1999 May 5;1411(2-3):334-50
10320667
Psychopharmacology (Berl). 2003 Apr;166(4):366-72
12589527